Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AnsellANSLF +10.50%72 5-Year Yield-on-Cost % is 2.22 as of Jul. 15, 2026, which is 7% above its 10-year median of 2.07. GuruFocus rates ANSLF with a GF Score™ of 72/100 and a GF Value™ of $18.84 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 326 Medical Devices & Instruments companies, Ansell ranks worse than 52.15% on this metric.
Ansell's yield on cost for the quarter that ended in Dec. 2025 was 2.22.
The historical rank and industry rank for Ansell's 5-Year Yield-on-Cost % or its related term are showing as below:
ANSLF'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.41 Med: 2.07 Max: 3.78
Current: 2.22
During the past 13 years, Ansell's highest Yield on Cost was 3.78. The lowest was 1.41. And the median was 2.07.
ANSLF's 5-Year Yield-on-Cost % is ranked worse than 52.15% of 326
companies
in the Medical Devices & Instruments industry
Industry Median: 2.325
vs ANSLF: 2.22
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Ansell 5-Year Yield-on-Cost % Related Terms
ANSLF vs ISRG, BDX, MDLN: 5-Year Yield-on-Cost % Comparison
For the Medical Instruments & Supplies subindustry, Ansell's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ansell 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ansell's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Ansell's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Ansell is calculated as
Ansell (ANSLF) has a 5-Year Yield-on-Cost % of 2.22 as of Jul. 15, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Ansell and its competitors. This is near median its historical median of 2.07. Over the past decade, Ansell's 5-Year Yield-on-Cost % has ranged from 1.41 to 3.78. According to the industry distribution chart, Ansell ranks #170 out of 326 companies in the Medical Devices & Instruments industry, placing it in the top 52.1%.
Is Ansell's 5-Year Yield-on-Cost % too high?
Ansell's current 5-Year Yield-on-Cost % of 2.22 is near median its 10-year median of 2.07. Over the past 10 years, this metric has ranged from a low of 1.41 to a high of 3.78. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.33. Ansell's value of 2.22 is 4.5% below this industry median. Based on the distribution chart, Ansell ranks #170 out of 326 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Ansell has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ansell's 5-Year Yield-on-Cost % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Ansell ranks #170 out of 326 companies for 5-Year Yield-on-Cost %. This places Ansell in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.33. Ansell's value of 2.22 is 4.5% below this benchmark. Historically, Ansell's own 5-Year Yield-on-Cost % has ranged from 1.41 to 3.78 over the past decade. While the company's 10-year median is 2.07 vs. the industry median of 2.33, Ansell has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.33, based on 326 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ansell's current 5-Year Yield-on-Cost % of 2.22 is 4.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Ansell and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ansell's current 5-Year Yield-on-Cost % is 2.22, which is near median its own 10-year median of 2.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ansell stock overvalued right now?
Based on GuruFocus' analysis, Ansell (ANSLF) is currently considered Modestly Overvalued. The stock's GF Value™ is $18.84, compared to a current price of $21.64 — trading 14.8% above its estimated fair value. The current 5-Year Yield-on-Cost % is 2.22, which is near median its 10-year median of 2.07 and 4.5% below the Medical Devices & Instruments industry median of 2.33. Ansell's overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Ansell (ANSLF), the current 5-Year Yield-on-Cost % is 2.22 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ansell (ANSLF) Overvalued in 2026?
Based on GuruFocus' analysis, Ansell stock appears to be overvalued.
The current stock price of $21.64 is trading 14.8% above its estimated GF Value™ of $18.84.
GuruFocus considers Ansell to be Modestly Overvalued.
Key valuation signals for ANSLF:
5-Year Yield-on-Cost %: 2.22 (near median its 10-year median of 2.07)
GF Value™: $18.84 vs. price of $21.64 (14.8% above fair value)
Industry Position: 4.5% below the Medical Devices & Instruments median (#170 of 326)
No single metric tells the full story. See the ANSLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ansell is a leading supplier of protective gloves for use in healthcare and industrial settings, earning approximately 55% of revenue and operating profit from the healthcare segment and the remainder from the industrial segment. The company holds a large number of patents, and the majority of sales come from its key branded product ranges. Ansell has a global manufacturing and distribution footprint and distributes via key partners as well as directly. Largest sales regions are North America and Europe, Middle East, and Africa. Asia-Pacific and Latin America, combined, are about one-fourth of sales.
72GF Score
Get the complete analysis for ANSLF
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANSLF has been successfully added to your 
